Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026
Same author

Azacitidine-induced remission enables allogeneic transplantation in <i>TET2</i>/<i>BCOR</i>-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report.

Haematologica·2026
Same author

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Blood advances·2026
Same author

Protein <i>S</i>-acylation dynamics provide metabolic plasticity to acute myeloid leukemia cells.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 16, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.5K

Leukemia circulation kinetics revealed through blood exchange method.

Alex B Miller1,2, Adam Langenbucher2,3, Felicia H Rodriguez2,4

  • 1Harvard-MIT Department of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Boston, MA, USA.

Biorxiv : the Preprint Server for Biology
|September 21, 2023
PubMed
Summary

Circulating leukemia cells clear much slower than solid tumor cells. Leukemia presence and treatment status significantly impact leukemia cell clearance from the blood.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K

Related Experiment Videos

Last Updated: Jul 16, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.5K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.1K

Area of Science:

  • Hematology
  • Cancer Biology
  • Immunology

Background:

  • Leukemia and bone marrow microenvironments change dynamically during disease progression.
  • Little is known about leukemia cell circulation kinetics and factors influencing circulating leukemia cell (CLC) clearance.

Approach:

  • Utilized a blood exchange method in mouse models of acute leukemia to study CLC dynamics.
  • Quantified the impact of microenvironmental factors on CLC clearance properties.

Key Points:

  • CLCs circulate 1-2 orders of magnitude longer than circulating tumor cells from solid tumors.
  • Leukemia presence in the marrow can impede CLC clearance in acute lymphocytic leukemia (ALL).
  • CLCs in relapsed acute myeloid leukemia (AML) models demonstrate faster clearance than untreated counterparts.

Conclusions:

  • CLC clearance rates are variable and influenced by tumor and treatment status.
  • E-selectin, a vascular adhesion molecule, affects CLC clearance.
  • Developed a strategy to identify factors governing circulating cell kinetics in leukemia.